Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
Article in English | MEDLINE | ID: mdl-38663717

ABSTRACT

To report a unique case of a patient who developed simultaneous bilateral maculopathy presumed from intake of fluoxetine. The optic coherence tomography (OCT) macular showed a subfoveal disruption in the outer retinal layer in both eyes (OU), higher in the left one (OS). Although reported cases of serotonin recapture inhibitors (SSRIs) Maculopathy so far have been caused by sertraline, fluoxetine shares the biological mechanism, and OCT findings and ocular symptoms are the same as published. We should be aware with ocular symptoms in patients that take fluoxetine.

3.
Rev. Hosp. Ital. B. Aires (2004) ; 43(3): 116-120, sept. 2023. ilus, tab
Article in Spanish | BINACIS, LILACS, UNISALUD | ID: biblio-1517444

ABSTRACT

Introducción: la depresión es un trastorno cada vez más prevalente alrededor del mundo. Los médicos generales son los profesionales de la salud más consultados por pacientes deprimidos. Más del 70% de los pacientes con depresión son vistos por médicos generales y no por especialistas en Psiquiatría. Según estudios realizados en Buenos Aires, más del 25% de los pacientes internados en Servicios de Clínica Médica en hospitales generales presenta depresión. Estos pacientes suelen ser atendidos y seguidos por médicos en formación, sean residentes o concurrentes de Clínica Médica. El objetivo del trabajo fue analizar el conocimiento sobre los inhibidores selectivos de la recaptura de serotonina (ISRS) que tienen los médicos residentes y concurrentes de Clínica Médica de 5 hospitales de la Ciudad Autónoma de Buenos Aires (CABA) y describir el tratamiento de un paciente depresivo por ellos. Material y métodos: se realizó un estudio descriptivo de corte transversal con un muestreo de tipo no probabilístico. Se utilizó como instrumento de medición un cuestionario semiestructurado organizado en dos secciones, una de datos demográficos que permiten caracterizar la muestra. La otra, de 15 ítems, explora los conocimientos sobre los ISRS y el tratamiento de la depresión. Dicho cuestionario fue revisado por 4 expertos. El instrumento es anónimo. Se aplicó a 59 médicos en formación en Clínica Médica, residentes y concurrentes, de 5 hospitales de la CABA, que participaron de forma voluntaria, durante el período agosto-septiembre de 2022. Resultados: la mayoría de los médicos en formación en Clínica Médica no tratan cuadros depresivos y, ante un paciente deprimido, solicitan la evaluación por un especialista en Salud Mental. Solo un 6,8% lo medica con un antidepresivo. Más del 75% de la muestra refiere recordar los conocimientos que tiene sobre de los ISRS de la cursada de Farmacología y un 13,6 de la cursada de Psiquiatría en la Facultad de Medicina. Conclusión: se observa un conocimiento deficitario sobre los ISRS en médicos residentes y concurrentes de Clínica Médica. Se considera necesario reforzar la formación sobre depresión y manejo de antidepresivos durante la residencia/concurrencia de Clínica Médica. (AU)


Introduction: depression is an increasingly common disorder around the world. General practitioners are the most frequently consulted health professionals by depressed patients. More than 70% of all depressed patients receive treatment by general practitioners and not by psychiatric specialists. According to studies conducted in Buenos Aires, more than 25% of all patients admitted to the Clinical Services in public hospitals present depression. These patients are usually under the care and follow-up of clinical trainee physicians, residents, or interns.This study aimed to analyze the knowledge about selective serotonin reuptake inhibitors (SSRIs) of clinical trainee residents and interns in five hospitals in the Ciudad Autónoma de Buenos Aires (CABA) and to describe their treatment of a depressive patient. Material and methods: we conducted a descriptive cross-sectional study with a non-probabilistic sampling. We used a semi-structured questionnaire arranged into two sections as a measuring tool. One, with demographic data to describe the sample. The other, with 15 items, explores respondents' knowledge of SSRIs and the treatment of depression. Four experts reviewed the questionnaire, which was anonymous. We applied it to 59 clinical medical trainees, residents, and interns from five CABA hospitals who volunteered to participate during August-September 2022. Results: most clinical trainees do not treat depressive conditions and, when confronted with a depressed patient, request an assessment by a Mental Health specialist. Only 6.8% medicate the patient with an antidepressant. More than 75% of the sample reported remembering their knowledge of SSRIs from the Pharmacology course and 13.6% from the Psychiatry course at the School of Medicine. Conclusion: there is a deficient knowledge about SSRIs in trainee residents and interns of Clínica Médica. We believe it is necessary to reinforce training on depression and management of antidepressants during residency/internship practice in Clínica Médica. (AU)


Subject(s)
Humans , Male , Female , Adult , Selective Serotonin Reuptake Inhibitors/administration & dosage , Depression/drug therapy , Education, Medical , Medical Staff, Hospital/education , Antidepressive Agents/administration & dosage , Reaction Time/drug effects , Cross-Sectional Studies , Surveys and Questionnaires , Selective Serotonin Reuptake Inhibitors/adverse effects , Selective Serotonin Reuptake Inhibitors/pharmacology , Age and Sex Distribution , Antidepressive Agents/adverse effects , Antidepressive Agents/pharmacology
4.
J. Health Biol. Sci. (Online) ; 10(1): 1-12, 01/jan./2022. tab, graf
Article in English | LILACS | ID: biblio-1382369

ABSTRACT

Objective: this systematic review aims to compile literature data on the antimicrobial action of Selective Serotonin Reuptake Inhibitors (SSRI). Methods: To this end, the articles in this review were searched in the PubMed database between the years 2010 to 2020, using terms found in MESH as descriptors. The PRISMA flow diagram was used to analyze the process flow of the research. Later, inclusion and exclusion criteria and eligibility for data extraction and statistical analysis were applied. Results: Thus, of 252 articles found, 13 were used for this systematic review. The period in which there were more publications was in 2016-2017. All articles demonstrated the antimicrobial activity of ISRS, such as sertraline, fluoxetine, and paroxetine, in addition to their synergistic activity with some antifungals and antibacterial. Conclusion: With this, it could be concluded that the repositioning of non-antibiotic drugs that have antimicrobial activity is a promising alternative for the scientific community and, in the future, in clinical practice


Objetivo: compilar dados da literatura sobre a ação antimicrobiana dos Inibidores Seletivos de Recaptação de Serotonina (ISRS). Métodos: os artigos desta revisão foram pesquisados na base de dados PubMed, entre os anos de 2010 a 2020, utilizando, como descritores, termos encontrados no MESH. O fluxograma PRISMA foi utilizado para analisar o fluxo do processo da pesquisa. Posteriormente, foram aplicados os critérios de inclusão e exclusão e de elegibilidade para extração de dados e análise estatística. Resultados: dos 252 artigos encontrados, 13 foram utilizados para esta revisão sistemática. O período em que houve mais publicações foi em 2016-2017. Todos os artigos demonstraram a atividade antimicrobiana do ISRS, como sertralina, fluoxetina e paroxetina, além de sua atividade sinérgica com alguns antifúngicos e antibacterianos. Conclusão: o reposicionamento de medicamentos não antibióticos que possuam atividade antimicrobiana é uma alternativa promissora para a comunidade científica e, futuramente, na prática clínica.


Subject(s)
Selective Serotonin Reuptake Inhibitors , Anti-Bacterial Agents , Antifungal Agents , Bacteria , Serotonin , Fluoxetine , Selective Serotonin Reuptake Inhibitors , Paroxetine , Sertraline , PubMed , Fungi
5.
Rev. Ateneo Argent. Odontol ; 66(1): 34-46, 2022. ilus, tab
Article in Spanish | LILACS | ID: biblio-1380253

ABSTRACT

La población mayor de 60 años es el grupo etario de mayor crecimiento en el mundo. Debido a que la depresión es una patología frecuente en la persona adulta mayor y anciana, los inhibidores de la recap- tación de la serotonina (ISRS) son el tratamiento de primera línea de elección. Este trabajo referencia la asociación del consumo de estos fármacos con la disminución de la densidad ósea mineral (DMO), el riesgo de fracturas y su repercusión en la atención odontológica. Además, incluye una breve descripción de la homeostasis ósea y la relación depresión-carga alostática. El trabajo interdisciplinario y una correcta anamnesis pueden detectar posibles complicaciones y riesgos vinculados con este tipo de medicamen- tos. Ello facilitaría un mejor manejo, más aún en el adulto mayor, donde una pequeña variable puede repercutir en su integridad (AU)


The population over 60 is the fastest growing age group in the world. Depression is a frequent pathology in the elderly and the elderly, with serotonin reuptake inhibitors (SSRI) being the 1st line treatment of choice. The association of the consumption of this drug with a decrease in bone mineral density (BMD), risk of fractures and its impact on dental care are referenced in this work. In addition, it includes a brief description of bone homeostasis and the depression-allostatic load relationship. Interdisciplinary work and a correct anamnesis can detect possible complications and risks linked to this type of medication, facilitating better management and even more so in the elderly, where a small variable can affect their integrity (AU)


Subject(s)
Humans , Male , Female , Aged , Aged, 80 and over , Dental Care for Aged/methods , Selective Serotonin Reuptake Inhibitors/adverse effects , Depression/complications , Antidepressive Agents/adverse effects , Bone Density/drug effects , Dental Implants/adverse effects , Risk Factors , Age Factors , Bone Remodeling/physiology , Selective Serotonin Reuptake Inhibitors/therapeutic use , Dental Restoration Failure , Fractures, Bone/prevention & control , Allostasis , Homeostasis
8.
Neuro Oncol ; 22(3): 318-332, 2020 03 05.
Article in English | MEDLINE | ID: mdl-31790121

ABSTRACT

BACKGROUND: This systematic review reports on outcomes and toxicities following stereotactic radiosurgery (SRS) for non-functioning pituitary adenomas (NFAs) and presents consensus opinions regarding appropriate patient management. METHODS: Using the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses, a systematic review was performed from articles of ≥10 patients with NFAs published prior to May 2018 from the Medline database using the key words "radiosurgery" and "pituitary" and/or "adenoma." Weighted random effects models were used to calculate pooled outcome estimates. RESULTS: Of the 678 abstracts reviewed, 35 full-text articles were included describing the outcomes of 2671 patients treated between 1971 and 2017 with either single fraction SRS or hypofractionated stereotactic radiotherapy (HSRT). All studies were retrospective (level IV evidence). SRS was used in 27 studies (median dose: 15 Gy, range: 5-35 Gy) and HSRT in 8 studies (median total dose: 21 Gy, range: 12-25 Gy, delivered in 3-5 fractions). The 5-year random effects local control estimate after SRS was 94% (95% CI: 93.0-96.0%) and 97.0% (95% CI: 93.0-98.0%) after HSRT. The 10-year local control random effects estimate after SRS was 83.0% (95% CI: 77.0-88.0%). Post-SRS hypopituitarism was the most common treatment-related toxicity observed, with a random effects estimate of 21.0% (95% CI: 15.0-27.0%), whereas visual dysfunction or other cranial nerve injuries were uncommon (range: 0-7%). CONCLUSIONS: SRS is an effective and safe treatment for patients with NFAs. Encouraging short-term data support HSRT for select patients, and mature outcomes are needed before definitive recommendations can be made. Clinical practice opinions were developed on behalf of the International Stereotactic Radiosurgery Society (ISRS).


Subject(s)
Adenoma/radiotherapy , Pituitary Neoplasms/radiotherapy , Radiosurgery/adverse effects , Disease Management , Humans , Radiation Dose Hypofractionation , Societies, Medical , Treatment Outcome
9.
J Clin Neurosci ; 57: 6-12, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30145088

ABSTRACT

OBJECTIVE: Currently no firm consensus exists regarding utilization of stereotactic radiosurgery (SRS) alone versus whole brain radiation (WBRT) ±â€¯SRS in patients with multiple brain metastases. The International Gamma Knife Research Foundation conducted a survey to review international practice patterns. METHODS: Through 2 international radiosurgery societies, clinicians who are involved in the radiosurgical management of patients with brain metastases were invited to complete a questionnaire. Respondents selected therapeutic options based on brief case vignettes and could select (1) SRS alone, (2) SRS with adjuvant WBRT, (3) WBRT alone, or (4) omission of upfront local radiation. RESULTS: A total of 71 respondents replied to the survey, including 41 radiation oncologists (57%), 24 neurosurgeons (34%), and 6 (8%) other clinicians. For a patient with 7 brain metastases (NSCLC), all under 1 cm, and stable extracranial disease, 77% would perform SRS alone and 17% would recommend WBRT alone. For a patient with 7 or more brain metastases, the majority selected SRS alone, irrespective of tumor histology (p > 0.5). However, neurosurgeons would more often utilize SRS alone or SRS combined with WBRT compared to radiation oncologists (p = 0.002). Key clinical factors in selection were KPS (82% of respondents), total tumor volume (81%), number (80%), and less-so histology (42%). CONCLUSION: Regardless of number of metastases, patients with small total volume of brain disease, high KPS, or who are receiving novel therapies are often recommended to undergo SRS. Neurosurgeons more often recommend SRS, emphasizing the importance of additional studies to clarify the role of SRS in these patients.


Subject(s)
Brain Neoplasms/radiotherapy , Brain Neoplasms/surgery , Cranial Irradiation/statistics & numerical data , Radiosurgery/statistics & numerical data , Surveys and Questionnaires , Adult , Aged , Attitude of Health Personnel , Female , Humans , Internationality , Male , Middle Aged , Tumor Burden
10.
J Neurosurg ; 130(3): 733-757, 2018 04 27.
Article in English | MEDLINE | ID: mdl-29701555

ABSTRACT

OBJECTIVES: The aims of this systematic review are to provide an objective summary of the published literature specific to the treatment of classical trigeminal neuralgia with stereotactic radiosurgery (RS) and to develop consensus guideline recommendations for the use of RS, as endorsed by the International Society of Stereotactic Radiosurgery (ISRS). METHODS: The authors performed a systematic review of the English-language literature from 1951 up to December 2015 using the Embase, PubMed, and MEDLINE databases. The following MeSH terms were used in a title and abstract screening: "radiosurgery" AND "trigeminal." Of the 585 initial results obtained, the authors performed a full text screening of 185 studies and ultimately found 65 eligible studies. Guideline recommendations were based on level of evidence and level of consensus, the latter predefined as at least 85% agreement among the ISRS guideline committee members. RESULTS: The results for 65 studies (6461 patients) are reported: 45 Gamma Knife RS (GKS) studies (5687 patients [88%]), 11 linear accelerator (LINAC) RS studies (511 patients [8%]), and 9 CyberKnife RS (CKR) studies (263 patients [4%]). With the exception of one prospective study, all studies were retrospective.The mean maximal doses were 71.1-90.1 Gy (prescribed at the 100% isodose line) for GKS, 83.3 Gy for LINAC, and 64.3-80.5 Gy for CKR (the latter two prescribed at the 80% or 90% isodose lines, respectively). The ranges of maximal doses were as follows: 60-97 Gy for GKS, 50-90 Gy for LINAC, and 66-90 Gy for CKR.Actuarial initial freedom from pain (FFP) without medication ranged from 28.6% to 100% (mean 53.1%, median 52.1%) for GKS, from 17.3% to 76% (mean 49.3%, median 43.2%) for LINAC, and from 40% to 72% (mean 56.3%, median 58%) for CKR. Specific to hypesthesia, the crude rates (all Barrow Neurological Institute Pain Intensity Scale scores included) ranged from 0% to 68.8% (mean 21.7%, median 19%) for GKS, from 11.4% to 49.7% (mean 27.6%, median 28.5%) for LINAC, and from 11.8% to 51.2% (mean 29.1%, median 18.7%) for CKR. Other complications included dysesthesias, paresthesias, dry eye, deafferentation pain, and keratitis. Hypesthesia and paresthesia occurred as complications only when the anterior retrogasserian portion of the trigeminal nerve was targeted, whereas the other listed complications occurred when the root entry zone was targeted. Recurrence rates ranged from 0% to 52.2% (mean 24.6%, median 23%) for GKS, from 19% to 63% (mean 32.2%, median 29%) for LINAC, and from 15.8% to 33% (mean 25.8%, median 27.2%) for CKR. Two GKS series reported 30% and 45.3% of patients who were pain free without medication at 10 years. CONCLUSIONS: The literature is limited in its level of evidence, with only one comparative randomized trial (1 vs 2 isocenters) reported to date. At present, one can conclude that RS is a safe and effective therapy for drug-resistant trigeminal neuralgia. A number of consensus statements have been made and endorsed by the ISRS.


Subject(s)
Radiosurgery/methods , Trigeminal Neuralgia/surgery , Humans , Radiosurgery/statistics & numerical data , Treatment Outcome
11.
Encephale ; 44(3): 291-296, 2018 Jun.
Article in French | MEDLINE | ID: mdl-29248119

ABSTRACT

INTRODUCTION: Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) are frequently prescribed. These antidepressants can potentially induce serious hyponatremia through the SIADH syndrome. That seems to concern all molecules of these classes but the individual risk of each molecule is not well known. The aims of the study were to compare the incidence rate of each molecule in order to identify the existence of molecules more at risk of inducing hyponatremia and to characterize a profile of patients at risk for hyponatremia during a treatment with a SSRI or a SNRI. METHOD: The cases of hyponatremia under SSRI/SNRI were extracted from the French pharmacovigilance database (BPNV). The exposition to the different SSRIs/SNRIs in the French population was estimated from the French National Health Insurance database (SNIIRAM) using a sampled database (Echantillon Généralistes des Bénéficiaires). The study ran from 01/01/2011 to 31/12/2013. The primary study endpoint was the incidence rate of notifications of the hyponatremia cases in patients treated by SSRI/SNRI and recorded into the BNPV database, related to the average annual number of corresponding treatments initiated during the same period. RESULTS: The number of cases of hyponatremia included in the study was 169 for 3 749 800 adult patients initiating treatment. The incidence rate of cases was 1.64 for 100 000 persons per year (PY). The standardized incidence rates between the different molecules showed no difference except for duloxetine (2.79/100 000 PY p > 0.03). Identified risk factors were age, with a large increase of incidence rate from 75 years old (incidence 12.5 higher) and female gender. CONCLUSIONS: Comparison of the incidence rates from spontaneous reports indicates a greater risk of hyponatremia for duloxetine for 2011-2013. This result needs to be confirmed by other studies. The advanced age and female sex are risk factors, irrespective of the molecule.


Subject(s)
Adrenergic Uptake Inhibitors/adverse effects , Hyponatremia/chemically induced , Hyponatremia/epidemiology , Selective Serotonin Reuptake Inhibitors/adverse effects , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Databases, Factual , Duloxetine Hydrochloride/adverse effects , Duloxetine Hydrochloride/therapeutic use , Female , France/epidemiology , Humans , Incidence , Male , Middle Aged , National Health Programs/statistics & numerical data , Pharmacovigilance , Risk Factors , Serotonin Syndrome/physiopathology , Sex Factors , Young Adult
12.
J Neurosurg Spine ; 27(4): 428-435, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28708043

ABSTRACT

OBJECTIVE Spinal metastases that recur after conventional palliative radiotherapy have historically been difficult to manage due to concerns of spinal cord toxicity in the retreatment setting. Spine stereotactic body radiation therapy (SBRT), also known as stereotactic radiosurgery, is emerging as an effective and safe means of delivering ablative doses to these recurrent tumors. The authors performed a systematic review of the literature to determine the clinical efficacy and safety of spine SBRT specific to previously irradiated spinal metastases. METHODS A systematic literature review was conducted, which was specific to SBRT to the spine, using MEDLINE, Embase, Cochrane Evidence-Based Medicine Database, National Guideline Clearinghouse, and CMA Infobase, with further bibliographic review of appropriate articles. Research questions included: 1) Is retreatment spine SBRT efficacious with respect to local control and symptom control? 2) Is retreatment spine SBRT safe? RESULTS The initial literature search retrieved 2263 articles. Of these articles, 160 were potentially relevant, 105 were selected for in-depth review, and 9 studies met all inclusion criteria for analysis. All studies were single-institution series, including 4 retrospective, 3 retrospective series of prospective databases, 1 prospective, and 1 Phase I/II prospective study (low- or very low-quality data). The results indicated that spine SBRT is effective, with a median 1-year local control rate of 76% (range 66%-90%). Improvement in patients' pain scores post-SBRT ranged from 65% to 81%. Treatment delivery was safe, with crude rates of vertebral body fracture of 12% (range 0%-22%) and radiation-induced myelopathy of 1.2%. CONCLUSIONS This systematic literature review suggests that SBRT to previously irradiated spinal metastases is safe and effective with respect to both local control and pain relief. Although the evidence is limited to low-quality data, SBRT can be a recommended treatment option for reirradiation.


Subject(s)
Radiosurgery , Re-Irradiation , Spinal Neoplasms/radiotherapy , Spinal Neoplasms/secondary , Cancer Pain/radiotherapy , Humans , Radiosurgery/methods , Spinal Neoplasms/complications
13.
J Neurosurg Spine ; 27(3): 295-302, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28598293

ABSTRACT

OBJECTIVE The aim of this systematic review was to provide an objective summary of the published literature pertaining to the use of stereotactic body radiation therapy (SBRT) specific to previously untreated spinal metastases. METHODS The authors performed a systematic review, using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, of the literature found in a search of Medline, PubMed, Embase, and the Cochrane Library up to March 2015. The search strategy was limited to publications in the English language. RESULTS A total of 14 full-text articles were included in the analysis. All studies were retrospective except for 2 studies, which were prospective. A total of 1024 treated spinal lesions were analyzed. The median follow-up time ranged from 9 to 49 months. A range of dose-fractionation schemes was used, the most common of which were 16-24 Gy/1 fraction (fx), 24 Gy/2 fx, 24-27 Gy/3 fx, and 30-35 Gy/5 fx. In studies that reported crude results regarding in-field local tumor control, 346 (85%) of 407 lesions remained controlled. For studies that reported actuarial values, the weighted average revealed a 90% 1-year local control rate. Only 3 studies reported data on complete pain response, and the weighted average of these results yielded a complete pain response rate of 54%. The most common toxicity was new or progressing vertebral compression fracture, which was observed in 9.4% of cases; 2 cases (0.2%) of neurologic injury were reported. CONCLUSION There is a paucity of prospective data specific to SBRT in patients with spinal metastases not otherwise irradiated. This systematic review found that SBRT is associated with favorable rates of local control (approximately 90% at 1 year) and complete pain response (approximately 50%), and low rates of serious adverse events were found. Practice guidelines are summarized based on these data and International Stereotactic Radiosurgery Society consensus.


Subject(s)
Radiosurgery , Spinal Neoplasms/radiotherapy , Spinal Neoplasms/secondary , Humans , Radiosurgery/adverse effects
14.
Rev. med. (Säo Paulo) ; 96(2): 103-115, 2017. ilus, tab
Article in English | LILACS | ID: biblio-868082

ABSTRACT

Introduction: Data have supported the influence of inflammation in the pathophysiology of depression and also the influence of depression in the development of a pro-inflammatory state. Major depressive disorder (MDD), the core depressive condition, has selective serotonin reuptake inhibitors (SSRI) as its first line pharmacological treatment. Efforts have been made to identify predictive factors for the responsiveness to SSRI. Therefore, we conducted this review to evaluate the hypothesis that baseline levels of inflammatory markers predict the responsiveness of MDD to SSRI treatment. Methods: A search in the PubMed database was made including the keywords ("SSRI" or "sertraline" or "citalopram" or "fluvoxamine" or "escitalopram" or "fluoxetine" or "paroxetine") and ("cytokines" or "CRP" or "TNF" or "inflammatory") and ("major depressive disorder" or "major depression"). Results: The search retrieved 245 manuscripts, from which 12 fulfilled our inclusion criteria. The analysis of these manuscripts suggested that high levels of interleukin-6 (IL-6), interleukin-1ß (IL-1ß), tumor necrosis factor-alpha (TNF-α) and c-reactive protein (CRP) at baseline might predict low responsiveness of MDD to SSRI treatment. Confounders such as cognitive impairment, chronicity and severity of depression, melancholic subtype, age and gender were not systematically included in the studies. Conclusion: Findings of this review suggest that high levels of pro-inflammatory markers at baseline might predict low responsiveness of MDD to SSRI treatment. Studies with adequate control for confounders are needed.


A influência da inflamação na fisiopatologia da depressão e o papel da depressão no desenvolvimento de um estado pró-inflamatório têm sido apoiados por diversos estudos. O transtorno depressivo maior (TDM), principal diagnóstico de depressão, tem os inibidores seletivos da recaptação de serotonina (ISRS) como tratamento farmacológico de primeira linha. Esforços têm sido feitos para identificar fatores preditivos da responsividade ao tratamento antidepressivo os ISRS. Portanto, esta revisão tem como objetivo avaliar a hipótese de que níveis basais de marcadores inflamatórios predizem a responsividade do TDM ao tratamento com ISRS. Métodos: Pesquisamos o banco de dados PubMed, incluindo as palavras-chave ("ISRS" ou "sertralina" ou "citalopram" ou "fluvoxamina" ou "escitalopram" ou "fluoxetina" ou "paroxetina") e ("citocinas" ou "CRP" ou "TNF" ou "inflamatório") e ("transtorno depressivo maior" ou "depressão maior"). Resultados:A pesquisa identificou 245 manuscritos, dos quais 12 satisfizeram os critérios de inclusão e exclusão e foram incluídos nesta revisão. A análise destes manuscritos sugeriu que níveis elevados de interleucina 6 (IL-6), interleucina 1ß (IL-1ß), fator de necrose tumoral ­ alfa (TNF-α) e proteína C-reativa (PCR) na avaliação basal podem prever baixa responsividade da depressão ao tratamento com ISRS. Fatores de confusão como deficiência cognitiva, cronicidade e gravidade da depressão, subtipo melancólico, idade e sexo, não foram sistematicamente incluídos nos estudos. Conclusão: Os achados desta revisão sugerem que níveis elevados de marcadores pró-inflamatórios na avaliação basal podem predizer baixa responsividade do TDM ao tratamento com ISRS. Estudos com controle adequado para fatores de confusão são necessários.


Subject(s)
Biomarkers , Cytokines , Depression/drug therapy , Inflammation , Selective Serotonin Reuptake Inhibitors , Antidepressive Agents/pharmacology , Predictive Value of Tests
15.
Front Psychol ; 7: 149, 2016.
Article in English | MEDLINE | ID: mdl-26941664

ABSTRACT

This is a case study of an adolescent who had largely overcome his early difficulty in learning to read, but continued to have severe problems with spelling. He had no visual memory impairment, and his letter-sound knowledge and phonemic awareness were at adult levels. Testing revealed that his difficulties in both reading and spelling only manifested when processing unfamiliar words. He was slow and inaccurate when reading non-words, despite a sublexical system dominated by the use of grapheme-phoneme units. It is suggested that limitations in the processing of the reading system were responsible for the lack of an extensive set of induced position-sensitive sublexical representations (ISRs) that are contextually dependent. This would have serious consequences for transfer to spelling.

16.
Rev. neuro-psiquiatr. (Impr.) ; 77(4): 226-235, oct. 2014. tab
Article in Spanish | LILACS, LIPECS | ID: lil-735460

ABSTRACT

Una aproximación diagnóstica y psicopatológica a la autolesión no suicida es planteada a partir de la recolección de datos de un grupo de diez adolescentes peruanas que sufrían esta patología. Se revisan las aproximaciones del DSM 5 a este diagnóstico, las que dan lugar a su configuración como una entidad que requiere mayor estudio para ser considerada como independiente de la sintomatología del trastorno límite de personalidad. Se formulan algunas tesis acerca de su psicopatología y las características que la singularizan frente a ese trastorno y la llamada conducta suicida. A partir de una formulación cognitivo-conductual, se examina el papel de esta sintomatología autolesiva como refuerzo automático y social, tanto en su vertiente positiva como la negativa. Ulteriormente se toman en cuenta las once creencias irracionales de Ellis como un instrumento para dilucidar la adaptación a la realidad de las pacientes que conformaron el grupo explorado. Finalmente se esbozan algunos alcances en torno a la terapia dialéctico-conductual de Linehan, mentalizing de Bateman y el uso del aripiprazol y los inhibidores selectivos de recaptación de serotonina (ISRS) en estos casos.


A psychopathological and diagnostic approach regarding non suicidal self-injury is proposed as a result of an exploratory study of a group of ten Peruvian adolescents suffering that condition. The DSM 5 status for this category is taken into account, as well as its relationship with entities like suicidal behavior and the borderline personality disorder diagnosis. On the basis of a cognitive-behavioral formulation, the meaning of this self damaging pathology in terms of automatic and social reinforcement, both positive and negative, is elucidated in order to clarify further developments. One of them being the use of Ellis’ irrational beliefs as a tool to evaluate the sense of reality of the patients. Some comments about Linehan’s dialectical behavioral psychotherapy, Bateman’s mentalizing and aripiprazole or selective serotonine reuptake inhibitors (SSRIs) in the treatment of these patients are proposed.


Subject(s)
Humans , Female , Adolescent , Self Mutilation/prevention & control , Self-Injurious Behavior , Adolescent Behavior/psychology , Surveys and Questionnaires , Suicidal Ideation , Psychopathology
17.
Encephale ; 40(1): 56-61, 2014 Feb.
Article in French | MEDLINE | ID: mdl-23810751

ABSTRACT

INTRODUCTION: SSRIs have been shown to affect bone health in adults, but this has been poorly studied in children. Given the frequency of SSRI prescription in children and adolescents, it is crucial to evaluate the impact of SSRIs on bone growth because the bone mass attained early in life is the most important predictor of a normal bone constitution. Experimental studies have demonstrated a direct functional role of serotonin in bone metabolism, independently of hyperprolactinemia or growth hormone levels. We have reviewed the literature on serotonin and bone metabolism, including experimental studies, clinical studies in adults as well as in the pediatric population. EXPERIMENTAL STUDIES: Experimental studies have shown that 5-HT transporter (5-HTT) is expressed in all kind of bone cells and is highly specific of the 5-HT recapture. 5-HTT inhibition by the SSRIs in these cells affects their function in vitro. Even though a few studies have suggested exposure to SSRIs could be beneficial by an anabolic effect on the trabecular bone, more concluding studies have demonstrated that SSRIs negatively affect bone growth, resulting in a specific bone phenotype including a reduction in bone mass, an altered bone architecture, and decreased mechanical properties. This phenotype is most probably the consequence of a decrease in bone formation, rather than an increase in bone resorption and is a direct and dose-dependent effect. However, many aspects of this bone effect of 5-HTT inhibition need to be further clarified, including the signal ways for 5-HTT and 5-HT receptors, origins of 5-HT in bone, and methods to isolate the inhibitory effect of 5-HTT specifically on bone. CLINICAL STUDIES: Metabolic and neuroendocrine side effects have been documented in children and adolescents taking SSRIs but the specific and direct effect of these molecules on bone metabolism has been poorly studied in this population. In adults, clinical studies have shown an association between the use of SSRIs and bone demineralization as well as reduction in bone mass, especially in the elderly and post-menopausal women. However, depression itself has been associated with a lower bone mass and increased risk of osteoporosis. In children, case reports show a decrease in growth due to a decreased secretion of growth hormone, but not by a direct effect. One cross-sectional study suggests a decrease in bone mass following SSRI treatment that is independent of variation in prolactin levels, but without elevation of fracture risk. These results, however, need to be replicated in further studies. CONCLUSION: Our review shows that experimental studies have demonstrated the implication of the serotonin system in bone metabolism. Mice with genetic disruption of 5-HTT have a bone phenotype of decreased bone mass, altered architecture, and decreased mechanical properties. Clinical studies exploring the effect of SSRIs on bone metabolism are scarce in children. However, results in adults tend to show a deleterious effect in the elderly. Regarding the frequency of SSRI prescription in the pediatric population, it is becoming urgent to better explore the effect of SSRIs on bone growth of children, as it can have major implications on the ulterior follow-up and on the precautions to take.


Subject(s)
Bone Density/drug effects , Bone Development/drug effects , Bone Development/physiology , Bone and Bones/drug effects , Selective Serotonin Reuptake Inhibitors/pharmacology , Absorptiometry, Photon , Adolescent , Adult , Animals , Bone Density/physiology , Bone and Bones/physiopathology , Child , Female , Humans , Male , Serotonin Plasma Membrane Transport Proteins/physiology
18.
Brasília méd ; 50(1): 47-50, july 2013.
Article in Portuguese | LILACS-Express | LILACS | ID: lil-686939

ABSTRACT

Ejaculação precoce é o problema sexual masculino mais comum, com prevalência de 2% a 23%. Este estudo é uma revisão do tratamento de ejaculação precoce em artigos de relevância publicados nas bases de dados PubMed, Lilacs e SciELO no período de 2006 a 2012. Discute-se sobre abordagens tópicas, medicações por via oral, acupuntura e drogas injetáveis. Os resultados mostram que a ejaculação precoce é problema de origem multifatorial e que diversos estudos estão sendo conduzidos sobre abordagens terapêuticas diferentes. O acompanhamento em longo prazo é fundamental para o tratamento e, em alguns casos, é importante que se realize terapia combinada. Ressalta-se que se deve aguardar os resultados de estudos que estão sendo desenvolvidos com novas drogas e terapias. Enquanto não houver novas conclusões, deve-se utilizar terapia medicamentosa por via oral e, em casos selecionados, terapia tópica.


Premature ejaculation is the most common sexual problem in men, with prevalence from 2% to 23%. This study is a review of relevant articles about the treatment of premature ejaculation published in the PubMed, Lilacs and SciELO databases between 2006 and 2012. We discuss topical approaches, oral medication, acupuncture and injectable drugs. The results of this study show that premature ejaculation is a multifactorial problem. In fact, many studies are being conducted on different therapeutic approaches to treat this condition. Long term follow-up is critical to treatment and, in some cases, combined therapy is important. We emphasize the relevance of waiting for the results of studies that are being conducted about new drugs and therapies. Oral medication and, in special cases, topical drugs, should be used while new conclusions are not reached.

19.
Article in Spanish | CUMED | ID: cum-54734

ABSTRACT

La eyaculación precoz o rápida (EP) constituye hoy, posiblemente la disfunción sexual más frecuente en el género masculino y está determinada por factores sociales, culturales y el establecimiento de métodos compensatorios. Es causante de serias afectaciones para la persona que la padece, ya sea en el plano social, psicológico o familiar. Su frecuencia es superior al de la disfunción eréctil, pero con mejores niveles de tolerancia. Entre los factores asociados a su aparición se encuentran causas biológicas, posibles endocrinopatías, predisposición genética y causas psicológicas. Entre las opciones terapéuticas se señalan los tratamientos psicoterapéuticos; desde las corrientes conductuales, agentes tópicos basados, en su gran mayoría, en Spray y cremas con componentes anestésicos. Otros como los tratamientos sistémicos se basan fundamentalmente en fármacos anestésicos y antidepresivos, así como la combinación de varios fármacos y métodos, lográndose entonces, mayores tasas de efectividad. Finalmente se propone en la actualidad la Dapoxetine, un antidepresivo (ISRS) con buenas tasas de respuesta. En el siguiente artículo se realizó una revisión del tema, profundizando en aspectos relacionados con la repuesta sexual masculina y su tratamiento. Con este objetivo se consultó los trabajos más actuales publicados en Pubmed y Medline.Conclusiones: La eyaculación rápida constituye un problema de salud a nivel mundial y pese a las variantes de tratamiento existentes todavía, se presenta resistencia masculina a su aceptación como trastorno y por tanto a su tratamiento. Los ISRS, y en especial la Dapoxetine, constituyen una variante de tratamiento efectiva(AU)


The premature ejaculation (PE) is nowadays probably the sexual dysfunction more frequent in the masculine sex and it is defined by social and cultural factors and the establishment of compensatory methods. Premature ejaculation causes several affections for the person who suffers from it in the social, psychological or family environment. Its frequency is higher than the dysfunction, but with better levels of acceptance. Among the associated factors that lead to its occurrence are the biological causes, the possible endocrinopathies, genetic tendency and psychological causes. Among the therapeutic options are shown the psychotherapeutic treatments from the tendencies of conduction, topic agents based in their majority on spray and creams with anesthetics components and other systemic treatments mainly based on anesthetics and ant depressive, as well as , the combination of methods and several pharmacs getting then greater levels of effectiveness. Finally, it is proposed the antidepressive Dapoxetine that shows good level of response. In the these paper was done a review of the theme deeping in aspect related with the masculine sexual answer and its treatment. With this objective the more updated works published in Pubmed and Medline were reviewed. Conclusions: The premature ejaculation is a world problem and although the several variables of treatment is still a masculine resistance to accept it as a disorder and therefore to its treatment. The SRSI and specially Dapoxetine constitute a variable of an effective treatmen(AU)


Subject(s)
Humans , Male , Premature Ejaculation/drug therapy , Premature Ejaculation/psychology
20.
J. bras. psiquiatr ; 61(1): 49-51, 2012.
Article in Portuguese | LILACS | ID: lil-623419

ABSTRACT

CONTEXTO: A acatisia é definida clinicamente como uma sensação de agitação associada à necessidade de produção de movimentos, comumente deflagrada por bloqueadores dopaminérgicos, como os neurolépticos, podendo ocorrer também durante o tratamento com inibidores seletivos de recaptação de serotonina. É possível que drogas não psiquiátricas que bloqueiem receptores dopaminérgicos, como a bromoprida, possam causar sintomas extrapiramidais. OBJETIVOS: Descrever um desfecho desfavorável caracterizado por acatisia em um paciente depressivo previamente estabilizado com fluvoxamina, após usar bromoprida. MÉTODOS: Descrição de um caso. RESULTADOS: Sr. J., paciente deprimido de 47 anos, estava estabilizado com fluvoxamina 200 mg por dia. Iniciou abruptamente com quadro de inquietação e necessidade de produzir movimentos voluntariamente a fim de aliviar esse desconforto. Há quatro dias havia iniciado o uso de bromoprida 30 mg por dia para tratamento de dispepsia. A suspensão da bromoprida promoveu alívio imediato dos sintomas. CONCLUSÃO: A bromoprida, um bloqueador dopaminérgico, pode ter deflagrado acatisia em um paciente em uso de fluvoxamina. Os mecanismos farmacológicos relacionados a esse desfecho são discutidos.


BACKGROUND: Akathisia is clinically defined as a sensation of restlessness associated to a necessity to produce movements, commonly triggered by dopaminergic blockers, like neuroleptics, and it might occur during treatment with selective serotonine reuptake inhibitors. It is possible that non psychiatric drugs that block dopaminergic receptors, like bromopride, might cause patients to develop extrapyramidal symptoms. OBJECTIVES: To describe an unfavorable outcome clinically characterized by akathisia in a depressed patient previously stabilized with fluvoxamine, after using bromopride. METHODS: Case report. RESULTS: Mr J, 47 year-old depressed patient, had been stabilized with fluvoxamine 200 mg a day. He began abruptly with restlessness and an urgency to produce voluntary movements in order to alleviate such discomfort. Four days earlier he began using bromopride 30 mg a day to treat dyspepsia. Withdrawn of bromopride promoted an immediate relieve of the symptoms. CONCLUSION: Bromopride, a dopaminergic blocker, might have triggered akathisia in a patient using fluvoxamine. The pharmacologic mechanisms regarding this outcome are discussed.

SELECTION OF CITATIONS
SEARCH DETAIL
...